Αποτελέσματα Αναζήτησης
5 Ιαν 2012 · The HSV vaccine was associated with an increased risk of local reactions as compared with the control vaccine, and it elicited ELISA and neutralizing antibodies to HSV-2. Overall, the...
- Maternal and Neonatal Herpes Simplex Virus Infections
Whether it is caused by herpes simplex virus (HSV) type 1 or...
- NEJM
Serologic surveys indicate that the prevalence of infection...
- Maternal and Neonatal Herpes Simplex Virus Infections
3 Ιουν 2016 · As current control strategies for genital HSV-2 infection, including antiviral therapy and condom use, are only partially effective, vaccines will be required to reduce infection. Both preventive and therapeutic vaccines for HSV-2 are being pursued and are in various stages of development.
Led by principal investigator Lesia K. Dropulic, M.D., of NIAID’s Laboratory of Infectious Diseases, the trial will test an investigational HSV-2 vaccine candidate, called HSV529, for safety and the ability to generate an immune system response.
30 Ιαν 2017 · GEN-003 is a candidate therapeutic vaccine containing HSV-2 gD2∆TMR and ICP4.2, and Matrix-M2 adjuvant. Methods. Persons with genital herpes were randomized into 3 dose cohorts to receive 3 intramuscular doses 21 days apart of 10 µg, 30 µg, or 100 µg of GEN-003, antigens without adjuvant, or placebo.
3 Ιουν 2016 · A therapeutic HSV-2 vaccine could reduce genital inflammation if viral shedding is contained; alternatively, therapeutic vaccines could result in increased genital inflammation as additional T-cells traffic to the genital tract, theoretically further increasing the risk of acquiring HIV.
24 Ιαν 2014 · Abstract. Herpes simplex virus type 2 (HSV-2), a globally sexually transmitted virus, and also one of the main causes of genital ulcer diseases, increases susceptibility to HIV-1. Effective vaccines to prevent HSV-2 infection are not yet available, but are currently being developed.
11 Μαρ 2016 · We will provide an overview of efforts to develop HSV-2 vaccines, including a discussion of the clinical need for an HSV vaccine, and status of research and development with an emphasis on recent insights from trials of vaccine candidates in clinical testing.
